Simplex Trading
HBIO icon

Simplex Trading’s Harvard Bioscience HBIO Stock Holding History

Simplex Trading’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-500
Closed -$3.35K – 9497
2025
Q4 		$3.35K Buy
+500
New +$2.97K ﹤0.01% 7634
2025
Q2 		– Sell
-610
Closed -$3K – 9076
2025
Q1 		$3K Sell
610
-260
-30% -$3.33K ﹤0.01% 7814
2024
Q4 		$18K Buy
870
+100
+13% +$2.3K ﹤0.01% 6763
2024
Q3 		$20K Buy
770
+270
+54% +$7.95K ﹤0.01% 6669
2024
Q2 		$14K Hold
500
– – ﹤0.01% 7181
2024
Q1 		$21K Buy
+500
New +$22.5K ﹤0.01% 7048
2022
Q2 		– Sell
-70
Closed -$4K – 10388
2022
Q1 		$4K Sell
70
-340
-83% -$20.1K ﹤0.01% 9559
2021
Q4 		$28K Buy
410
+190
+86% +$13.5K ﹤0.01% 7986
2021
Q3 		$18K Hold
220
– – ﹤0.01% 8517
2021
Q2 		$18K Buy
220
+219
+21,900% +$15.5K ﹤0.01% 8671
2021
Q1 		$5K Buy
+1
New +$49 ﹤0.01% 8203

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Simplex Trading's HBIO Position: Q1 2026 in Review

Simplex Trading sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 1,379 shares — an estimated $9.22K sold.

Simplex Trading first reported a position in HBIO in Q3 2017 and held it in 16 quarters. The position peaked at $29K in Q3 2018. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Simplex Trading reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 1,379 Harvard Bioscience shares in Q1 2026, an estimated $9.22K.
  • Simplex Trading first reported a position in Harvard Bioscience in Q3 2017 and held it in 16 quarters.
  • Simplex Trading's Harvard Bioscience position peaked at $29K in Q3 2018.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.